Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide 10 mg is a next-generation research peptide designed as a triple receptor agonist, targeting the GLP-1, GIP, and glucagon receptor pathways involved in metabolic regulation, energy balance, appetite signaling, insulin sensitivity, and substrate utilization.
As a multi-pathway metabolic compound, Retatrutide has gained significant attention in advanced obesity, body composition, and metabolic research due to its ability to engage complementary incretin and glucagon-related mechanisms within a single molecular platform.
Synthera Labs presents Retatrutide as part of its precision peptide system, integrating global API raw material sourcing, analytical documentation review, downstream processing, batch traceability, and QR-linked verification.
Product format: Lyophilized peptide
Concentration: 10 mg
Category: Metabolic Research
Pathways: GLP-1 / GIP / Glucagon
Use: Research use only
Supplier documentation for Retatrutide raw material includes COA parameters such as purity, assay, peptide content, residual solvent data, water content, endotoxin conformity, and mass spectrum confirmation. The uploaded HHDPharma COA lists Retatrutide CAS 2381089-83-2, batch HHD20250604, purity 99.35%, assay 99.7%, peptide content 92.5%, endotoxin conformity, and mass spectrum conformity.
The supplier HPLC report also shows a main chromatographic peak at 13.989 min with an area percentage of 99.4506% at 220 nm, supporting the purity profile of the analyzed sample.
Disclaimer: This product is intended for laboratory research purposes only. Not for human consumption, diagnostic use, therapeutic use, or clinical application.
Retatrutide 10 mg is a next-generation research peptide designed as a triple receptor agonist, targeting the GLP-1, GIP, and glucagon receptor pathways involved in metabolic regulation, energy balance, appetite signaling, insulin sensitivity, and substrate utilization.
As a multi-pathway metabolic compound, Retatrutide has gained significant attention in advanced obesity, body composition, and metabolic research due to its ability to engage complementary incretin and glucagon-related mechanisms within a single molecular platform.
Synthera Labs presents Retatrutide as part of its precision peptide system, integrating global API raw material sourcing, analytical documentation review, downstream processing, batch traceability, and QR-linked verification.
Product format: Lyophilized peptide
Concentration: 10 mg
Category: Metabolic Research
Pathways: GLP-1 / GIP / Glucagon
Use: Research use only
Supplier documentation for Retatrutide raw material includes COA parameters such as purity, assay, peptide content, residual solvent data, water content, endotoxin conformity, and mass spectrum confirmation. The uploaded HHDPharma COA lists Retatrutide CAS 2381089-83-2, batch HHD20250604, purity 99.35%, assay 99.7%, peptide content 92.5%, endotoxin conformity, and mass spectrum conformity.
The supplier HPLC report also shows a main chromatographic peak at 13.989 min with an area percentage of 99.4506% at 220 nm, supporting the purity profile of the analyzed sample.
Disclaimer: This product is intended for laboratory research purposes only. Not for human consumption, diagnostic use, therapeutic use, or clinical application.